Jaguar Health, Inc.

JAGX Nasdaq CIK: 0001585608

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 200 PINE STREET SUITE 400, SAN FRANCISCO, CA, 94104
Mailing Address 200 PINE STREET SUITE 400, SAN FRANCISCO, CA, 94104
Phone 415-371-8300
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
DEF 14A Definitive proxy statement March 24, 2026 View on SEC
4 Insider stock transaction report March 12, 2026 View on SEC
8-K Current report of material events March 9, 2026 View on SEC
8-K Current report of material events March 6, 2026 View on SEC
8-K Current report of material events March 3, 2026 View on SEC
8-K Current report of material events February 18, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 10, 2026 View on SEC
8-K Current report of material events January 23, 2026 View on SEC
4 Insider stock transaction report January 21, 2026 View on SEC
4 Insider stock transaction report January 21, 2026 View on SEC

Material Events

8-K Financial Distress March 6, 2026
High Impact
  • Jaguar Health received a delisting warning from Nasdaq on March 5, 2026, for failing to meet the $1.00 minimum bid price.
  • The company does not qualify for the standard 180-day grace period due to significant reverse stock splits (1-for-250 or greater) within the past two years.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.